Alerta

Stabilisation medium for extending temporal viability of human semen

Resumen de: GB2704849A

A stabilization medium (optionally having a pH between 7.2-8) for extending temporal viability of human semen for up to a predetermined time period when mixed therewith and maintained within a predetermined temperature range, comprising: one or more pH buffer agents (optionally comprising MOPS or HEPES in a concentration range of 10.0-25.0 mmol); one or more inorganic salts (optionally selected from sodium chloride, potassium chloride, magnesium sulfate heptahydrate, sodium phosphate dihydrate, sodium bicarbonate and calcium chloride dihydrate); one or more organic compounds (optionally selected from glucose, sodium lactate (L-isomer), sodium pyruvate and taurine); and one or more amino acids with antioxidant properties (optionally selected from alanine, aspartate, asparagine, glutamate, alanyl-glutamine, glycine, proline and serine). The stabilization medium may further comprise at least one of: one or more antioxidants (selected from a group comprising acetyl-L-carnitine, alpha-lipoic acid and N-acetyl-L-cysteine); one or more pH-altering compounds (selected from a group comprising sodium dihydrogen phosphate dihydrate, magnesium sulfate heptahydrate, calcium chloride dihydrate, sodium lactate (L-isomer) and sodium pyruvate); one or more antibiotics and chelating agents. The predetermined time period may be up to 72 hours and the predetermined temperature range may be 36.1-37.2 degrees Celsius. Figure 2

NETWORK TOPOLOGY FOR INSULIN PUMP SYSTEMS

Resumen de: EP4811834A2

In one implementation, an insulin delivery system using an on-body network includes an insulin delivery device that is adapted to administer dosages of insulin to a patient; a controller that is adapted to control operation of the insulin delivery device, to establish a first network connection in which the controller acts in a central role, and to establish a second network connection in which the controller acts in a peripheral role; one or more peripheral devices that are adapted to generate patient data related to blood glucose levels and to transmit the patient data wirelessly over the first network connection, the peripheral devices acting in a peripheral role over the first network connection; and a mobile application installed on a mobile computing device that is programmed to communicate with the controller over the second network connection, the mobile application communicating in a central role over the second network connection.

WIRELESS GLUCOSE MONITORING SYSTEM WITH REPLACEABLE TRANSMITTER PATCH

Resumen de: WO2025106281A1

Sensor systems are provided that include (i) a sensor configured to obtain sensor data indicative of an analyte level of a user's body, (ii) a first transmitter patch configured in size and shape to overlay the sensor during a first time period of use, (iii) a second transmitter patch configured in size and shape to overlay the sensor during a second time period of use. First sensor data is transmitted from the sensor to the first transmitter patch corresponding to the first time period and second sensor data is transmitted from the sensor to the second transmitter patch corresponding to the second time period. The first transmitter patch can be replaced by the second transmitter patch without removing the sensor.

COMPATIBILITY CHECK FOR CONTINUOUS GLUCOSE MONITORING APPLICATION

Resumen de: EP4809909A2

0001 Disclosed are systems, methods, and articles for determining compatibility of a mobile application and operating system on a mobile device. In some aspects, a method includes receiving one or more data values from a mobile device having a mobile medical software application installed thereon, the data value(s) characterizing a version of the software application, a version of an operating system installed on the mobile device, and one or more attributes of the mobile device; determining whether the mobile medical software application is compatible with the operating system by at least comparing the received data value(s) to one or more test values in a configuration file; and sending a message to the mobile device based on the determining, the message causing the software application to operate in one or more of a normal mode, a safe mode, and a non-operational mode.

PERSONALIZED CLOSED-LOOP ARTIFICIAL PANCREAS SYSTEM

Resumen de: EP4810079A1

0001 The invention discloses a personalized closed-loop artificial pancreas system, comprising: a detection mechanism, an infusion mechanism, and a program mechanism, at least based on the blood glucose value detected by the detection mechanism, the program mechanism generates an insulin infusion instruction and controls the infusion mechanism to perform the infusion, the program mechanism comprises a user interface, and in response to an input from the patient, the program mechanism performs a corresponding meal mode function, the meal mode comprises a high carbohydrate mode and a normal carbohydrate mode. Based on the patient's input, the program mechanism executes the functions of high carbohydrate mode or normal carbohydrate mode, which can be suitable for people with different carbohydrate consumption habits, improve the adaptability of closed-loop artificial pancreas to different populations, and enable people with different carbohydrate consumption habits to maintain satisfactory blood glucose control effects.

WIRELESS GLUCOSE MONITORING SYSTEM WITH DYNAMIC COMMUNICATION MANAGEMENT

Resumen de: WO2025106280A1

Techniques are provided for dynamically managing wireless communications of glucose monitoring systems. The systems dynamically adjust the communication session intervals based on various dynamic conditions. Some systems are also configured with an antenna positioned on an opposing side of a chip from other sensor electronics and/or outside of an encasing of potting material to enhance the signaling functionality of the antenna.

SYSTEM AND METHOD FOR WIRELESS COMMUNICATION OF GLUCOSE DATA

Resumen de: US2018027104A1

Systems, devices, and methods are disclosed for wireless communication of analyte data. One such method includes, during a first interval, establishing a first connection between an analyte sensor system and a display device. During the first connection, the method includes exchanging information related to authentication between the analyte sensor system and the display device. The method includes making a determination regarding whether authentication was performed during the first interval. During a second interval, the method may include establishing a second connection between the analyte sensor system and the display device for transmission of an encrypted analyte value, and bypassing the exchanging of information related to authentication performed during the first connection. The method also includes, during the second interval, the analyte sensor system transmitting the encrypted analyte value to the display device, if the determination indicates that the authentication was performed during the first interval.

DYNAMIC EQUIVALENT ON BOARD ESTIMATOR

Resumen de: US20260279537A1

Adaptive on board estimation of exogenous pharmacon responsive to transient (i.e., impermanent) physiological effects is provided. Dynamically estimating an equivalent amount of an exogenous pharmacon on board (XOB), such as insulin and/or carbohydrates, left in the subject, is based on predictions of glucose time-series data. These estimated values, such as insulin on board (IOB), are useful for diabetes management software, including decision support and/or artificial pancreas (AP) algorithms, for example.

Senolytic car-T cells targeting uPAR, a cell surface and secreted senescence biomarker

Resumen de: AU2026205448A1

Abstract Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express a uPAR-specific chimeric antigen receptor. Also disclosed herein are methods for using the engineered immune cells of the present technology to treat or ameliorate the effects of cancer and senescence-associated pathologies (e.g., lung fibrosis, atherosclerosis, Alzheimer's disease, diabetes, liver fibrosis, chronic kidney disease, aging, or osteoarthritis) by selectively targeting senescent cells. Also provided herein are methods for detecting the senescent cell burden in a patient. Abstract

APPLICATOR FOR CONTINUOUS BLOOD GLUCOSE MEASUREMENT DEVICE

Resumen de: US20260272337A1

The present disclosure relates to a continuous blood glucose measurement device and an applicator, wherein the continuous blood glucose measurement device is produced in a state in which a body attachment unit has been assembled inside an applicator, so as to minimize a user's additional work of attaching the body attachment unit to the body, thereby enabling the body attachment unit to be attached to the body only by simply activating the applicator. Particularly, the present invention provides a continuous blood glucose measurement device and an applicator, wherein the continuous blood glucose measurement device: includes a wireless communication chip in a body attachment unit so as to enable communication with an external terminal, thereby enabling simple and convenient use thereof, without additional work for connecting a separate transmitter, and easier maintenance; and is activated by a user's operation after the body attachment unit is attached to the body, so as to enable the operation start time to be adjusted to an appropriate time according to user's needs, and to enable the operation to start in a stabilized state so that blood glucose can be measured more accurately.

TECHNIQUES FOR DETERMINING AUTOMATED INSULIN DELIVERY DOSAGES

Resumen de: US20260273184A1

Methods and apparatuses for performing an insulin infusion process are described. For example, an apparatus may include at least one memory and logic coupled to the at least one memory. The logic may operate to determine a basal parameter for a patient based on a type 2 diabetes (T2D) multiple daily injection (MDI) information of the patient, the basal parameter indicating a basal infusion rate, determine an additional insulin (Iadd) value based on a mean blood glucose difference (BGdiff) information associated with the patient, determine an insulin volume to infuse into the patient based on the basal parameter and Iadd, and administer the insulin volume to the patient. Other embodiments are described.

AUTOMATED SCREENING FOR DIABETIC RETINOPATHY SEVERITY USING COLOR FUNDUS IMAGE DATA

Resumen de: US20260279578A1

Methods and systems for evaluating diabetic retinopathy (DR) severity are provided herein. Color fundus imaging data is received for an eye being evaluated for DR. A metric is generated using the color fundus imaging data, the metric indicating a probability that a score for the DR severity in the eye falls within a selected range.

METHODS OF ESTIMATING BLOOD GLUCOSE AND RELATED SYSTEMS

Resumen de: US20260276659A1

A method includes estimating a value of a parameter indicative of an age or lifespan of a population of red blood cells of a subject, estimating a value of average glucose (AG) of the subject based on (i) the value of the parameter and (ii) a value indicative of an amount of glycated hemoglobin (HbA1c) of the subject, and providing information for treatment or diagnosis of a hyperglycemia condition of the subject based on the estimated value of AG.

IMPROVED CELL IMPLANTS AND METHODS OF USING THE SAME

Resumen de: WO2026193167A1

The present disclosure provides modified cells for use in cell therapies to treat diabetes, as well as methods for preparing such cells. More specifically, the present disclosure provides genetically modified cells that reduce the production of extracellular matrix following implantation and/or express a novel peptide that targets the cells for destruction without impacting the subject's native cells.

MATURATION MEDIUM COMPOSITIONS AND METHODS FOR HUMAN HEART ORGANOID MATURATION

Resumen de: US20260275292A1

A maturation medium and a method for maturing an early embryonic human heart organoid into a mature human heart organoid are provided herein. The maturation medium includes a cell growth medium containing a medium supplement including one or more fatty acid, triiodothyronine (T3) growth hormone, insulin, one or more antioxidant, a sugar, and carnitine; one or more additional fatty acid; an additional carnitine or creatine; and an additional T3 growth hormone. The maturation medium may further include one or more of an additional sugar, an additional antioxidant, and a growth factor. The method includes contacting an early embryonic human heart organoid with one or more maturation medium to produce a mature human heart organoid.

SOLUTION FOR SUSPENDING CELLS, AND USE THEREOF

Resumen de: US20260275287A1

An object of the present invention is to provide a solution for thawing that can maintain or improve the cytotoxic activity of highly active NK cells and the like after thawing. A solution for suspending cells for administration to humans, which satisfies the following criteria: (1) containing potassium ion, (2) having a pH of 4.9 or higher, (3) not containing chloride ions at a concentration of 135 mEq/L or higher, (4) not containing glucose at a concentration of 5.55 mM or higher, (5) not containing calcium ions at a concentration of 0.423 mM or higher, (6) having an osmolarity of 200 to 396 mOsm, and (7) containing any organic acid(s) selected from the group consisting of succinic acid, malic acid, lactic acid, citric acid, and acetic acid.

METHODS OF EVADING IMMUNE REJECTION

Resumen de: US20260273059A1

The present disclosure is directed to methods, compositions and devices capable of avoiding foreign body responses to implanted material. This technology utilizes polymer encapsulated engineered cells that produce natural, cell-generated cytokines to elicit a tailored immune response to implanted materials for applications in diabetes, immune tolerance, and organ transplantation.

CUSTOMIZED WEARABLE SALIVA BIOSENSOR FOR REAL-TIME CONTINUOUS HEALTH MONITORING

Resumen de: US20260272335A1

A customized wearable saliva biosensor system for continuous, real-time, in-situ monitoring of biochemical markers in human saliva. The system integrates a multi-gate organic electrochemical transistor biosensor employing an organic semiconductor channel with enzyme-functionalized gate electrodes, a compact wireless integrated circuit with Bluetooth data transmission, a power subsystem optionally incorporating piezoelectric and/or triboelectric nanogenerators, and a custom-fitted wearable substrate fabricated from a three-dimensional scan of the user's dental anatomy. The system is positioned within the oral cavity in proximity to the sublingual glands for direct detection of fresh saliva at the point of secretion. A differential measurement architecture comparing an enzyme gate to a control gate provides selective, real-time detection of target biomarkers including glucose, lactate, and uric acid. Measured data is wirelessly transmitted to a companion mobile application for display to the user.

NONINVASIVE DEVICE TO ESTIMATE AND TRACK BLOOD GLUCOSE LEVELS

Resumen de: WO2026193386A1

Systems and methods for estimating and tracking blood glucose levels are provided. A method includes receiving, from a sensor, a plurality of photoplethysmography (PPG) signals, deriving an oxygenated hemoglobin concentration signal and a deoxygenated hemoglobin concentration signal from the PPG signals, determining a phase relationship between the oxygenated hemoglobin concentration signal and the deoxygenated hemoglobin concentration signal, generating a glycemic pointer based at least in part on the phase relationship, and generating a first blood glucose level based on the glycemic pointer.

BLOOD GLUCOSE INSIGHT GENERATOR FOR DRIVING APPLICATIONS

Resumen de: US20260272353A1

Systems and methods are described for monitoring blood glucose when driving. The methods may include receiving blood glucose input for a user over a time period, detecting one or more driving events associated with the user over the time period, correlating the blood glucose input with the one or more driving events; determining, based on the correlation, at least one pattern indicating a blood glucose status for the user, generating, based on the blood glucose status and a repository of user data, at least one insight or trend corresponding to the user, and causing presentation of the at least one insight or trend.

METHODS AND SYSTEMS TO OPTIMIZE GLUCOSE MONITORING USING VOICE ANALYSIS

Resumen de: US20260272336A1

A method for monitoring a subject’s blood glucose level, comprising: receiving a voiceprint from the subject; correlating the received voiceprint to a determined blood glucose level for the subject, using a predefined correlation model; determining, by comparing the determined blood glucose level to a predetermined acceptable blood glucose level range for the subject, whether the determined blood glucose level is outside the predetermined acceptable blood glucose level range for the subject; and generating an alert when the determined blood glucose level is outside the predetermined acceptable blood glucose level range for the subject.

SYSTEMS AND METHODS FOR AN ARTIFICIAL INTELLIGENCE HEALTH COACH WITH BIOMETRIC DATA INTEGRATION AND PERSONALIZED HEALTH INTERVENTION GENERATION

Resumen de: US20260279592A1

A method uses an artificial intelligence health coach system that includes receiving a voice input from a user, interpreting the voice input with natural language processing performed by an artificial intelligence model, which includes a large language model, and receiving a glucose level from a continuous glucose monitor. The method further includes receiving an insulin level from a database, calculating a Homeostatic Model Assessment of Insulin Resistance score from the glucose level and the insulin level, comparing the score to historical scores associated with the user, and identifying a predicted risk of a hyperglycemic episode. The method also includes generating a preventative health recommendation modified based on whether the score has changed over time, requesting additional health information from the user, modifying the recommendation based on the additional information, and outputting the modified recommendation to the user. The method maintains persistent user data as contextual memory across interactions.

ARTIFICIAL PANCREAS SIMULATOR

Resumen de: WO2026192089A1

The present invention relates to an artificial pancreas simulator and, more particularly, may comprise an infusion pump for administering insulin to a user, a blood glucose meter for measuring the user's blood glucose level at predetermined intervals, a user terminal for communicating with the infusion pump and the blood glucose meter, and an organ simulator for simulating bodily functions of the user related to changes in the user's blood glucose level.

SMART MEDICAL MONITORING WRISTBAND

Resumen de: WO2026192544A1

The invention is a smart medical monitoring wristband developed for use in the healthcare sector. The wristband detects health parameters such as blood pressure, heart rate, oxygen saturation, body temperature, ECG, and blood sugar, and provides real-time remote access to this data. The wristband facilitates easy access to patients for healthcare professionals while enhancing patient comfort by providing music, games, and educational content. Additionally, it increases the number of patients under supervision through an emergency call button and GPS tracking system. Using AI-powered data analysis, it detects abnormal health conditions and automatically notifies the healthcare team. With its lightweight and ergonomic design prioritizing patient comfort, the device can be used securely with encrypted data.

SENSOR APPLICATOR ASSEMBLY FOR CONTINUOUS GLUCOSE MONITORING SYSTEM

Nº publicación: EP4806354A2 16/09/2026

Solicitante:

I SENS INC [KR]
i-Sens, Inc.

Resumen de: EP4806354A2

0001 The present invention relates to a sensor applicator assembly for a continuous glucose monitoring system and provides a sensor applicator assembly for a continuous glucose monitoring system, which is manufactured with a sensor module assembled inside an applicator, thereby minimizing additional work by a user for attaching the sensor module to the body and allowing the sensor module to be attached to the body simply by operating the applicator, and thus can be used more conveniently. A battery is built in the sensor module and a separate transmitter is connected to the sensor module so as to receive power supply from the sensor module and be continuously used semi-permanently, thereby making the assembly economical. The sensor module and the applicator are used as disposables, thereby allowing accurate and safe use and convenient maintenance.